摘要
目的对治疗成人非重症社区获得性肺炎(CAP)的6种经验性抗感染方案进行药物经济学评价。方法采用回顾性研究方法,选取2015年1月至2016年12月收住呼吸内科普通病区治疗的CAP患者325例。按照给药方案的不同分为6组,从临床治疗效果、感染性指标、细菌清除率三方面评价治疗效果并进行成本效果分析。结果 6种方案的治疗效果无显著性差异(P> 0.05),通过成本效果分析,左氧氟沙星组成本效果比值最低。单因素敏感性分析结果与成本效果分析一致。结论左氧氟沙星用于经验性治疗成人非重症CAP疗效与其他5组疗效相当,但治疗费用最低。
Objective To analyze the pharmacoeconomic evaluation of six empirical anti-infective regimens for the treatment of adults non-severe community-acquired pneumonia (CAP). Method Retrospective study method was used to select patients who were admitted to the department of respiratory in the hospital from January 2015 to December 2016, who were given comprehensive treatment according to the diagnostic criteria of CAP. The patients were divided into six groups using antimicrobial agents. The therapeutic effects of each regimen were investigated from three aspects of clinical efficacy, laboratory examination index and pathogen elimination, and each antimicrobial regimen was analyzed by means of cost effect analysis. Results All of the six treatments have good treatment effects. By cost-effectiveness analysis(CEA),levofloxacin treatment group had the lowest cost-effectiveness rate. The results of sensitivity analysis showed that the results of CEA was stable. Conclusion Levofloxacin had similar efficacy as the other 5 groups,but the treatment cost was the lowest in the empirical treatment of adult non-severe CAP.
作者
周媛
王勇
ZHOU Yuan;WANG Yong(Dept. of Pharmacy,Zhujiang Hospital of Southern Medical University,Guangzhou Guangdong 510080,China)
出处
《昆明医科大学学报》
CAS
2019年第4期76-81,共6页
Journal of Kunming Medical University
基金
云南省科技厅-昆明医科大学应用基础研究联合专项基金资助项目(2015FB083)
